Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrialPhase |
NCT00264810
|
| gptkbp:conditionStudied |
medically refractory partial onset epilepsy
|
| gptkbp:endDate |
2011
|
| gptkbp:FDAApprovalSupported |
NeuroPace RNS System
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:participants |
191
|
| gptkbp:period |
Phase III
|
| gptkbp:result |
seizure frequency reduction
|
| gptkbp:resultPublication |
NEJM 2013;369:1407-1417
|
| gptkbp:sponsor |
NeuroPace, Inc.
|
| gptkbp:startDate |
2005
|
| gptkbp:studiedDevice |
NeuroPace RNS System
|
| gptkbp:bfsParent |
gptkb:Responsive_Neurostimulation_System
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
NeuroPace Pivotal Trial
|